Stock Ratings / Health Care / CORT / financials

CYTK (28) ARWR (58) TGTX (63) PTGX (65) ⌘ Pro Terminal →

Corcept Therapeutics Incorporated (CORT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Where is CORT trading relative to its 50-day, 200-day, and 52-week technical levels?

CORT last traded at $81.12 (-5.62% on volume of 1,429,434 shares), positioning the stock -26.03% below its 50-day simple moving average ($109.66) and +7.44% above its 200-day simple moving average ($75.50). Across its 52-week range of $28.66 to $126.38, CORT sits at the 53.7% percentile with a 14-day RSI of 27.6 (OVERSOLD (<32)) and an implied next-earnings move of ±10.3% ($72.76 to $89.48).

Q: How profitable is Corcept Therapeutics Incorporated (CORT)?

In FY 2025 (10-K), CORT converted $761.4M of revenue into a 98.3% gross margin, 5.9% operating margin, and $141.8M in free cash flow (18.6% FCF margin).

$81.12 -5.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $80.15

Corcept Therapeutics Incorporated (CORT) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $8.77B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CORT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Corcept Therapeutics Incorporated (NASDAQ: CORT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $81.12 (-5.62% 1D, market cap $8.77B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CORT ranks #137 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CORT compare to CYTK and ARWR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CORT carries a Roarable C (63/100 RQD), trailing P/E of 93.2x, gross margin of 96.0%, and ROIC of 4.8%. By comparison, CYTK (Cytokinetics Incorporated) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $8.76B) and ARWR (Arrowhead Pharmaceuticals Inc.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC 11.1%, cap $8.46B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CORT?

▼

Per CORT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001088856), Corcept Therapeutics Incorporated generated $761.4M in revenue (+12.8% YoY), $99.7M in net income, and $141.8M in free cash flow against $836.7M in total assets and $85.0M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $80.15 (-1.20%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 18.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk A-

Each axis scored 0–20

12M PRICE TARGET CONE+2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CORT)Realized 20D OHLCV Swing Band: ±10.3%

Deterministic 5-Pillar Attribution (63/100 Composite)

🔍 WHY CORT SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (29% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Macro Regime Fit+15/20 pts (24% of score)

FRED Regime × Technicals: 54% of 52W Range • RSI-14 at 27.6 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$116.23+0% Next Q

Q2 (-2Q)

Grade B-$116.28-25.8% Next Q

Q3 (-1Q)

Grade B-$86.28-6% Next Q

Current

Grade C$81.12+0.9% Hist 90D α

Trajectory: B (71) → C (63)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CORT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, CORT faces multiple-compression risk if 93.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Priced at 93x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($109.66) or 200D SMA ($75.50) invalidates the momentum regime and cuts Target Base ($82.95) toward Bear Floor ($64.70).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CORT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CORT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 63%NO 37%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How CORT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$141.8M (18.6% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $482.4M

FY24

Rev $675.0M

FY25

Rev $761.4M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$761.4M	98.3%	5.9%	$99.7M	$141.8M	5.8%
FY 2024	$675.0M	98.4%	20.3%	$141.2M	$196.1M	17.3%
FY 2023	$482.4M	92%	22.2%	$106.1M	$105.0M	2.7%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CORT)

✓Walkthrough of CORT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CORT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +57.21%🛡️ HOLDING TREND SUPPORT

2026-11-03O $85.95H $85.95L $81.12C $81.12VOL 1.43M

RES: $121.1SUP: $80.10SMA50: $109.7SMA200: $75.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CORT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CORT Butterfly Map → + Track CORT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +12.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CORT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CORT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CORT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CORT)

Health Care Rank #137 of 1016 ⚔️ CYTK vs CORT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CORT vs. CYTK, ARWR, TGTX, PTGX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Corcept Therapeutics Incorporated (CORT) ranks #137 by composite RQD confidence (63/100, grade C) and #122 by equity capitalization ($8.77B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. PTGX currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with CORT at 63/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CORT ACTIVE Corcept Therapeutics Incorporated	C	63/100	93.2x	96.0%	4.8%	-5.62%	$8.77B	Benchmark Subject
CYTK Cytokinetics Incorporated	E	28/100	—	—	-35.0%	-0.50%	$8.76B	/cytk-vs-cort →
ARWR Arrowhead Pharmaceuticals Inc.	D+	58/100	—	—	11.1%	-0.97%	$8.46B	/arwr-vs-cort →
TGTX TG Therapeutics Inc.	C	63/100	19.9x	83.7%	12.0%	+5.34%	$9.36B	/tgtx-vs-cort →
PTGX Protagonist Therapeutics Inc.	C	65/100	—	—	-16.7%	+0.35%	$9.37B	/ptgx-vs-cort →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001088856

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Corcept Therapeutics Incorporated (CORT) reported GAAP revenue of $761.4M (+12.8% vs. FY2024 revenue of $675.0M , and +57.8% cumulative change since FY2023) , GAAP net income of $99.7M, operating cash flow of $142.0M, and free cash flow of $141.8M (-27.7% YoY). On the balance sheet, CORT closed FY2025 with $836.7M in total assets against $85.0M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$761.4M	$99.7M	$142.0M	$141.8M	$836.7M	$85.0M
FY2024 (FY)	2024-12-31	$675.0M	$141.2M	$198.3M	$196.1M	$840.6M	$72.4M
FY2023 (FY)	2023-12-31	$482.4M	$106.1M	$126.7M	$105.0M	$5.11B	$1.20B

3. CORT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CORT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CORT compare to CYTK and ARWR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CORT?

Where is CORT trading relative to its 50-day, 200-day, and 52-week technical levels?

CORT last traded at $81.12 (-5.62% on volume of 1,429,434 shares), positioning the stock -26.03% below its 50-day simple moving average ($109.66) and +7.44% above its 200-day simple moving average ($75.50). Across its 52-week range of $28.66 to $126.38, CORT sits at the 53.7% percentile with a 14-day RSI of 27.6 (OVERSOLD (<32)) and an implied next-earnings move of ±10.3% ($72.76 to $89.48).

CORT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Corcept Therapeutics Incorporated (CORT)?

In FY 2025 (10-K), CORT converted $761.4M of revenue into a 98.3% gross margin, 5.9% operating margin, and $141.8M in free cash flow (18.6% FCF margin).

Direct Sub-Reports: CORT RQD Cockpit CORT 12M Forecast CORT Earnings & Move CORT Dividends & DRIP CORT Insiders & 13F CORT Whale Options CORT Profit Sankey CORT News & Why

ROARABLE RATING BRIEF • RQD 63/100 (C) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CORT — Corcept Therapeutics Incorporated: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:17:03Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CORT scores 64 out of 100, a letter grade of C, labeled "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:

Fundamental Cash Engine — 13 / 20: Per the RQD rating, ROIC is 4.8% and FCF yield is 1.53%. These figures signal that the business generates returns and cash relative to its valuation that are modest rather than strong, which limits the upside case on cash-flow grounds.
Whale 13F Flow — 9 / 20: Per the RQD rating, the institutional accumulation and options positioning reading is weak-to-neutral.
Insider Conviction — 9 / 20: Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow reads as neutral-to-weak. The <holders> section contains no transaction-level records for this assessment.
Macro Regime Fit — 15 / 20: Per the RQD rating, beta is 0.88, indicating the stock has moved less than the broad market, a defensive characteristic that supports this pillar.
Forensic Balance Sheet — 18 / 20: Per the RQD rating, Altman Z is 26, Piotroski F is 8/9, and Debt/Equity is 0.12. This is the strongest pillar and reflects low leverage and high financial-health scoring.

For a prospective investor, the composite reads as balanced: the balance sheet and low beta offer downside stability, while thin ROIC, weak flow signals, and a very high multiple temper the upside. The rating is descriptive of the source data and is not a recommendation.

Business

Corcept Therapeutics Incorporated is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, its market capitalization is $9.3B.

Recent Catalysts & News Wire Analysis

Per the recent news section, the wire carries six CORT items, all rated YELLOW under the MARKET WIRE label:

A Yahoo Finance report asks whether options traders are betting on a large move in the stock.
A Seeking Alpha headline reports the stock plunged 20% on Genmab cancer data.
A Benzinga headline reports the stock trading higher on a given day.
A Stock Titan item notes a listen-only webcast accompanying the Q3 update at 5 p.m. ET on Nov. 3.
A Stock Traders Daily piece covers rotational strategy timing.
A Stock Titan item reports a director's trust selling 10,000 shares under a trading plan.

Risk watch items include the reported 20% decline tied to Genmab cancer data and the director's trust sale. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals. The Genmab-related headline in the news wire is the only cross-company reference in the sources, and its second-order implications for peers cannot be quantified from the data provided.

Open Questions

What is the revenue composition and product mix behind the FY 2025 revenue of $761.4M, and what drove the drop in operating income to $44.8M?
Is the FY 2023 debt of $1.20B a reporting artifact or a real balance sheet event, given the RQD forensic score assumes Debt/Equity of 0.12?
What is the content and magnitude of the Genmab cancer data referenced in the news wire, and how does it affect the pipeline?
What are the EPS figures for each fiscal year, since the financials report EPS as N/A throughout?
Who are the institutional holders and insiders behind the 13F and Form 4 pillar scores, given the holders section is empty?

CORT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Corcept Therapeutics Incorporated (CORT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CORT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 19h ago

Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock?

Yahoo Finance report covering Corcept Therapeutics Incorporated (CORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 22h ago

Corcept Therapeutics plunges 20% on Genmab cancer data (CORT:NASDAQ)

Seeking Alpha report covering Corcept Therapeutics Incorporated (CORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Why Is Corcept Therapeutics Stock Trading Higher Today? - Corcept Therapeutics (NASDAQ:CORT)

Benzinga report covering Corcept Therapeutics Incorporated (CORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A listen-only webcast will accompany Corcept’s Q3 update at 5 p.m. ET Nov. 3.

Stock Titan report covering Corcept Therapeutics Incorporated (CORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

How Corcept Therapeutics Incorporated (CORT) Affects Rotational Strategy Timing

Stock Traders Daily report covering Corcept Therapeutics Incorporated (CORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A director's trust sells 10,000 shares under a trading plan at Corcept Therapeutics (CORT).

Stock Titan report covering Corcept Therapeutics Incorporated (CORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Erasca, Inc. (ERAS), DICK’S Sporting Goods, Inc. (DKS), Corcept Therapeutics Incorporated (CORT), and Charter Communications, Inc. (CHTR)

GlobeNewswire report covering Corcept Therapeutics Incorporated (CORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Corcept Therapeutics (CORT) Climbs 2.24% to $121.19 as Buyers Reclaim Momentum - Pre-Earnings Momentum

https://www.siam.in/ report covering Corcept Therapeutics Incorporated (CORT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CORT Bull vs. Bear Conversation Board — What's Your Call at $81.12?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CORT 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $92.83 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CORT (C • RQD 64/100) a Buy at $85.95?

Welcome to the CORT (Corcept Therapeutics Incorporated) Roar Pit. Current RQD Composite is 64/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (93.2x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $67.04 (-22.0%)

Spot @ $85.95

Pump the brakes on CORT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CORT, but look at what you are paying: 93.2x trailing P/E with 96.0% gross margins. Unless Corcept Therapeutics Incorporated expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $103.14 (+20.0%)

Spot @ $85.95

CORT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CORT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $85.95 (52-wk range $28.66 - $126.38), any beat on forward guidance forces shorts and underweight funds to chase.